ACAD FY 2024 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$958M+31.8% YoY

Gross Profit

$876M91.5% margin

Operating Income

$231M24.1% margin

Net Income

$226M23.6% margin

EPS (Diluted)

$1.36

Cash Flow

Operating Cash Flow

$158M

Free Cash Flow

$157M

Stock-Based Comp.

$67M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$455M

Stockholders' Equity

$733M

Cash & Equivalents

$320M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$958M	$726M	+31.8%
Gross Profit	$876M	$681M	+28.7%
Operating Income	$231M	-$73M	+414.5%
Net Income	$226M	-$61M	+469.5%